{
    "code": "02024084",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=02024084",
    "time": "2023-04-14 03:27:36",
    "許可證字號": "衛署藥輸字第024084號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "113\/10\/14",
    "發證日期": "93\/10\/14",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原登錄字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA00202408405",
    "中文品名": "愛寧達注射劑",
    "英文品名": "ALIMTA (PEMETREXED FOR INJECTION) 500MG",
    "適應症": "1.ALIMTA 併用cisplatin 是治療局部晚期或轉移性非小細胞肺癌(顯著鱗狀細胞組織型除外)之第一線化療用藥。2 ALIMTA 單一藥物是局部晚期或轉移性非小細胞肺癌(顯著鱗狀細胞組織型除外)病人接受4 個週期含鉑藥物的第一線化療後疾病並未惡化之維持療法。3. ALIMTA 單一藥物是治療局部晚期或轉移性非小細胞肺癌(顯著鱗狀細胞組織型除外)之第二線治療用藥。4. ALIMTA與pembrolizumab及含鉑化學療法併用，做為轉移性，不具有EGFR或ALK腫瘤基因異常之非鱗狀非小細胞肺癌的第一線治療藥物。5. ALIMTA 與cisplatin 併用於治療惡性肋膜間質細胞瘤。",
    "劑型": "243凍晶注射劑",
    "包裝": "500公絲小瓶 、100支以下盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "管制藥品分類級別": "",
    "藥品分類": "",
    "監視期限": "",
    "主成分略述": "PEMETREXED DISODIUM HEPTAHYDRATE",
    "限制項目": "02輸　入",
    "申請商名稱": "1411301100  台灣禮來股份有限公司",
    "申請商地址": "台北市復興北路３６５號１１樓",
    "主製造廠": [
        {
            "製造廠名稱": "FGR0032000  VIANEX S.A. (PLANT C)",
            "製造廠廠址": "16TH KM MARATHONOS AVENUE,15351 PALLINI ATTIKIS, GREECE",
            "製造廠公司地址": "",
            "製造廠國別": "GREECE",
            "製程": "製造、分裝"
        }
    ],
    "次製造廠": [
        {
            "製造廠名稱": "FFR0118000  LILLY FRANCE",
            "製造廠廠址": "2 RUE DU COLONEL LILLY 67640 FEGERSHEIM, FRANCE",
            "製造廠公司地址": "13 RUE PAGES, 92158 SURESNES, FRANCE",
            "製造廠國別": "FRANCE",
            "製程": ""
        }
    ],
    "CCC號列": "30049071005 抗癌藥Anti-cancer preparations",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1004002410",
            "成分名稱": "PEMETREXED DISODIUM HEPTAHYDRATE",
            "含量描述": "",
            "含量": "713.0000000000",
            "單位": "MG"
        }
    ],
    "藥物辨識詳細資料": {
        "外觀尺寸": "",
        "特殊劑型": "",
        "顏色": "",
        "特殊氣味": "",
        "刻痕": "",
        "形狀": "",
        "標記一": "",
        "標記二": ""
    },
    "藥物辨識外觀圖片": [
        {
            "title": "Alimta 500-104-09-30(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02024084&Seq=001&Type=10"
        }
    ],
    "仿單外盒": [
        {
            "title": "20200601 Alimta-Final truth-ALM-0004-USPI-20190130+GOLD approved statement Dec08, Aug10_15Oct2019 v2 (CDE接受版) 加紅框- Clean-109-06-04.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02024084&Seq=111&Type=9"
        },
        {
            "title": "標籤_NL006FSTW00.pdf - proof report-109-06-04.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02024084&Seq=003&Type=8"
        },
        {
            "title": "外盒_NL004FSTW00.pdf - proof report-109-06-04.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02024084&Seq=002&Type=8"
        }
    ]
}